Abologix
Abologix is a biopharmaceutical company based in Geneva, Switzerland, focused on developing monoclonal antibodies targeting novel pharmacological targets for cancer treatment. Their mission is to develop best-in-class therapies by blocking specific molecules involved in cancer progression, such as JAM-C and Olfml3.
Industries
Nr. of Employees
small (1-50)
Abologix
C/o Fongit Rte de la Galaise 34 1228 Plan-les-Ouates Geneva, Switzerland
Products
Monoclonal antibody targeting Junction Adhesion Molecule C (JAM-C) — lead preclinical candidate
A selective monoclonal antibody that blocks JAM‑C, developed and advanced as a lead preclinical candidate for treatment of drug‑resistant B‑cell lymphomas and potentially JAM‑C–positive solid tumours; progressed through preclinical efficacy and safety studies in animal models.
Recombinant monoclonal antibodies targeting Olfactomedin-like protein 3 (Olfml3)
Recombinant monoclonal antibodies developed to block Olfml3, a protein associated with tumour angiogenesis and vascular growth factor pathways, intended as a strategy to inhibit tumour vascularization.
Monoclonal antibody targeting Junction Adhesion Molecule C (JAM-C) — lead preclinical candidate
A selective monoclonal antibody that blocks JAM‑C, developed and advanced as a lead preclinical candidate for treatment of drug‑resistant B‑cell lymphomas and potentially JAM‑C–positive solid tumours; progressed through preclinical efficacy and safety studies in animal models.
Recombinant monoclonal antibodies targeting Olfactomedin-like protein 3 (Olfml3)
Recombinant monoclonal antibodies developed to block Olfml3, a protein associated with tumour angiogenesis and vascular growth factor pathways, intended as a strategy to inhibit tumour vascularization.
Expertise Areas
- Monoclonal antibody development
- Oncology therapeutic development
- Target identification and validation
- Preclinical in vivo pharmacology
Key Technologies
- Monoclonal antibody engineering
- Recombinant protein/antibody expression
- In vivo tumour/lymphoma animal models
- Preclinical efficacy and safety assays
News & Updates
Abologix received 100,000 CHF from the KICK FUND to advance its preclinical development of monoclonal antibody H225, a JAM-C blocker.
Abologix completed an Innosuisse-funded program assessing the preclinical efficacy and safety of monoclonal antibody H225 in animal models of B-cell lymphoma, with excellent results.
Abologix nominated monoclonal antibody H225 as its lead preclinical candidate for treating drug-resistant B-cell lymphomas and JAM-C (+) solid tumors.
Abologix received 100,000 CHF from the KICK FUND to advance its preclinical development of monoclonal antibody H225, a JAM-C blocker.
Abologix completed an Innosuisse-funded program assessing the preclinical efficacy and safety of monoclonal antibody H225 in animal models of B-cell lymphoma, with excellent results.
Abologix nominated monoclonal antibody H225 as its lead preclinical candidate for treating drug-resistant B-cell lymphomas and JAM-C (+) solid tumors.